Eurofins Discovery has renewed its partnership with Dompé farmaceutici S.p.A. to further harness AI in drug discovery.
- The collaboration combines Eurofins’ comprehensive drug discovery capabilities with Dompé’s advanced AI platform.
- Eurofins Discovery specialises in optimised target screening, chemical synthesis, and data generation.
- Dompé’s Exscalate platform evaluates trillions of molecules using supercomputing and AI.
- This alliance aims to accelerate the discovery of novel therapeutics, ultimately enhancing human health.
Eurofins Discovery has announced the renewal of its collaborative venture with Italy-based Dompé farmaceutici S.p.A., marking the second year of this cutting-edge alliance. This partnership leverages Eurofins Discovery’s Integrated Drug Discovery capabilities and Dompé’s state-of-the-art AI platform to push the boundaries of drug research.
The renewed collaboration demonstrates the synergy between Eurofins’ robust drug discovery methods and Dompé’s prowess in AI-driven molecule evaluation via the Exscalate platform. Eurofins Discovery employs a blend of target-specific screening cascades, automated chemical synthesis, and high-quality data generation to optimise the drug discovery process.
With a track record of over 12,000 available assays, Eurofins excels in tackling complex biological challenges. The company’s expertise spans multiple domains, including protein production, high-throughput screening (HTS), custom assay design, biophysics, translational biology, ADME, and pharmacokinetics.
Dompé farmaceutici, a biopharmaceutical front-runner, operates the Exscalate platform. This powerful tool is instrumental in evaluating trillions of molecular candidates for each novel target. Dompé’s innovative use of supercomputing and AI data analytics underpins its global research initiatives.
The partnership is an exemplary model of how the collaborative use of AI and integrated drug discovery strategies can accelerate research timelines and improve outcomes in the quest for groundbreaking therapeutics. Both Eurofins and Dompé are committed to pushing forward with innovations that may potentially redefine future healthcare solutions.
This renewed collaboration exemplifies the transformative potential of combining AI and integrated drug discovery in advancing therapeutic research.
